| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 05/26/2005 | WO2005047316A2 Insulin releasing peptides |
| 05/26/2005 | WO2005047315A2 Optimized expression of hpv 58 l1 in yeast |
| 05/26/2005 | WO2005047314A2 Fgf-beta binding and supported peptides |
| 05/26/2005 | WO2005047309A2 Prophylactic and therapeutic monoclonal antibodies |
| 05/26/2005 | WO2005047306A2 A prion-like form of cpeb and related compositions and methods |
| 05/26/2005 | WO2005047305A2 Cellular membrane protein assay |
| 05/26/2005 | WO2005047302A1 Expression in filamentous fungi of protease inhibitors and variants thereof |
| 05/26/2005 | WO2005046732A2 Methods and compositions for the inhibition of hiv-1 replication |
| 05/26/2005 | WO2005046731A1 Interference with c-maf function in multiple myeloma |
| 05/26/2005 | WO2005046720A2 Diagnosis, prognosis and treatment of pulmonary diseases using foxa2 |
| 05/26/2005 | WO2005046716A1 Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia |
| 05/26/2005 | WO2005046714A2 Cytokine antagonist molecules |
| 05/26/2005 | WO2005046710A2 Tgf-beta binding and supported peptides |
| 05/26/2005 | WO2005046709A2 Tgf - beta binding and supported peptides |
| 05/26/2005 | WO2005046708A1 Selective inhibitors of nuclear factor-kb activation and uses thereof |
| 05/26/2005 | WO2005046701A1 Novel methods for administration of drugs and devices useful thereof |
| 05/26/2005 | WO2005046587A2 Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
| 05/26/2005 | WO2005046583A2 Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes |
| 05/26/2005 | WO2005046577A2 Human prostaglandin ep1 receptor variants and methods of using same |
| 05/26/2005 | WO2005046450A2 Method for diagnosis and treatment of pulmonary disorders |
| 05/26/2005 | WO2005046449A2 Soluble tcr molecules and methods of use |
| 05/26/2005 | WO2005026316A3 Alphavirus vaccines |
| 05/26/2005 | WO2005025624A3 The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases |
| 05/26/2005 | WO2005023845A3 Cyclic peptides acting as urotensin-ii antagonists |
| 05/26/2005 | WO2005019263A8 A continuous process for the assembly of macromolecular substances and the subsequent capture and isolation of a macromolecular assembly, and a system suitable for the process |
| 05/26/2005 | WO2005019255A8 Muteins of tear lipocalin |
| 05/26/2005 | WO2005016246A3 Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases |
| 05/26/2005 | WO2005014642A3 Novel multifunctional cytokines |
| 05/26/2005 | WO2005012516A3 Maize cellulose synthases and uses thereof |
| 05/26/2005 | WO2005012336A3 Uranium-chelating peptides and uses thereof |
| 05/26/2005 | WO2005009363A3 Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies |
| 05/26/2005 | WO2005009217A3 Diagnosis of pre-cancerous conditions using pcdgf agents |
| 05/26/2005 | WO2005005475A3 Appl proteins as rab5 effectors |
| 05/26/2005 | WO2005004899A3 Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung infections |
| 05/26/2005 | WO2005003158A3 Compositions and methods for increasing bone mineralization |
| 05/26/2005 | WO2004113520A3 Modulation of coffee flavour precursor levels in green coffee grains |
| 05/26/2005 | WO2004106937A3 Diagnostics and therapeutics for diseases associated with g protein-coupled p2y purinoreceptor 6 (p2y6) |
| 05/26/2005 | WO2004104591A3 Improvements to gamma delta t cell-mediated therapy |
| 05/26/2005 | WO2004100987A3 Methods of using il-1 antagonists to treat neointimal hyperplasia |
| 05/26/2005 | WO2004099784A3 Method for determining a tissue degradation process by detection of fibromodulin neoepitopes |
| 05/26/2005 | WO2004092356A3 Method for obtaining mastocyte lines from porcine tissue and method for production of heparin type molecules |
| 05/26/2005 | WO2004089975A3 Peptides of irf-1 |
| 05/26/2005 | WO2004089421A3 Methods for rational pegylation of proteins |
| 05/26/2005 | WO2004087924A3 Method for delivery of substances to intracellular microorganisms |
| 05/26/2005 | WO2004070016A3 System for expression of genes in plants |
| 05/26/2005 | WO2004063341A3 Hematopoietic stem cell niche cells |
| 05/26/2005 | WO2004062574A9 Improved linkers for radiopharmaceutical compounds |
| 05/26/2005 | WO2004058177A3 Crystals and structures of spleen tyrosine kinase sykkd |
| 05/26/2005 | WO2004044217A3 Dna sequences from tcd genomic region of photorhabdus luminescens |
| 05/26/2005 | WO2004044208A3 Food flours with specific technological characteristics and low allergenicity |
| 05/26/2005 | WO2004022719A3 Type 2 diabetes susceptibility genes |
| 05/26/2005 | WO2003085081A3 Nucleic acid and corresponding protein entitled 238p1b2 useful in treatment and detection of cancer |
| 05/26/2005 | WO2002093998A9 Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| 05/26/2005 | US20050114927 Virus-resistant transgenic plants expressing L3 |
| 05/26/2005 | US20050114924 Down-regulation and silencing of allergen genes in transgenic peanut plants |
| 05/26/2005 | US20050114914 linker for activation of T- cells (lat genes and proteins), used for screening drug useful for treatment against asthma and allergies |
| 05/26/2005 | US20050114912 Model for neurodegenerative disorders |
| 05/26/2005 | US20050114910 Transgenic mice having a human major histocompatibility complex (MHC) phenotype, experimental uses and applications |
| 05/26/2005 | US20050114109 STRUCTURE OF INTEGRIN ALPHA V-beta 3 EXTRACELLULAR DOMAIN COMPLEXED WITH LIGAND |
| 05/26/2005 | US20050114037 generating polymeric attachment sites on target proteins comprising inputting coordinates into computers for the target protein and using simulation modules on said coordinates to create a set of amino acid positions of said protein suitable for polymeric attachment; modification of therapeutic proteins |
| 05/26/2005 | US20050113568 Microarrays; animal husbandry; derived from Kagoshima Berkshire |
| 05/26/2005 | US20050113565 Pegylated factor VII glycoforms |
| 05/26/2005 | US20050113564 Chimeric receptors with 4-1BB stimulatory signaling domain |
| 05/26/2005 | US20050113563 Chemical peptide ligation with three or more components |
| 05/26/2005 | US20050113562 Antibodies directed against prothrombin fragment F1+2, the preparation and use thereof |
| 05/26/2005 | US20050113408 Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| 05/26/2005 | US20050113329 Contacing cell/body fluid with antibody which binds human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide; for inhibiting tumor growth; gene expression inhibition; immunization |
| 05/26/2005 | US20050113323 Introducing antisense nucleotides which are complementary to untranslated region of prostate tumor inducing gene |
| 05/26/2005 | US20050113305 Enhancing the efficacy of chemotherapy and/or radiotherapy by administering a specific inhibitory peptide, preferably before the therapy |
| 05/26/2005 | US20050113304 Recombinant expression system for production of a peptide capable of inhibiting the protease activity of Botulinum toxin B or tetanus toxin which expression system comprises a nucleotide sequence encoding the peptide operably linked to a control sequence for effecting expression |
| 05/26/2005 | US20050113303 Method for treating metabolic bone disease such as osteomalacia and osteoporosis in a patient by administering a compound that modulates phosphate regulating endopeptidase homolog (PEX) expression and/or PEX enzymatic activity |
| 05/26/2005 | US20050113302 Cardioprotective protein (A3P) or A3 receptor-mediated cardioprotective protein isoform (A3PI) exhibiting an altered expression in cardiac tissue in response to exposure to an A3 agonist; useful for clinical screening, diagnosis, prognosis, therapy, and prophylaxis |
| 05/26/2005 | US20050113298 Receptor binding peptides derived from the SARS S protein |
| 05/26/2005 | US20050113292 Protein mimetic for preventing HIV-1 entry to host cells of living subject through membrane fusion, wherein HIV-1 contains envelope glycoprotein gp41 that has plurality of peptides in pre-hairpin state, comprising at least two monomeric peptide strands and interstrand linker coupling peptide strands |
| 05/26/2005 | US20050113291 Use of a substance which binds to and initiates signaling of the human SARP-1 receptor or a substance which stimulates release or potentiates the activity of endogenous SARP-1 for the manufacture of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis |
| 05/26/2005 | US20050113289 Conjugate of hemoglobin covalently joined to a polysaccharide; for use as synthetic blood; preventing hemorrhagic shock |
| 05/26/2005 | US20050113288 Bonding tissues and cross-linking proteins with naphthalimide compounds |
| 05/26/2005 | US20050113284 Drug for regenerating tissue and vessel and method therefor |
| 05/26/2005 | US20050112750 Chitin degradative systems |
| 05/26/2005 | US20050112744 Glucose dehydrogenase fusion proteins and their use in expression systems |
| 05/26/2005 | US20050112734 Forming chemical intermediate, such as 2-ketogluconate, for ascorbic acid |
| 05/26/2005 | US20050112725 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 05/26/2005 | US20050112721 Chimeric peptide immunogens |
| 05/26/2005 | US20050112720 Soluble complexes of amylod beta peptide and peptidyl prolyl isomerase chaperone and methods of making and using them |
| 05/26/2005 | US20050112713 Methods of using Fab I and compounds modulating Fab I activity |
| 05/26/2005 | US20050112708 Oxidized fungal antigens and methods of making and using thereof |
| 05/26/2005 | US20050112702 Receptor binding assay wherein binding to the CLLD8 protein identifies the compound as being an agonist or antagonist; antiallergens |
| 05/26/2005 | US20050112692 Screening peptide library; incubation complexing |
| 05/26/2005 | US20050112683 Protein sequence analysis apparatus, methods, computer-readable media, computer programs, signals and data structures |
| 05/26/2005 | US20050112682 Green fluorescent fusion protein as diagnosis tool; quantitative analysis; colorimetic analysis |
| 05/26/2005 | US20050112681 Isolated human transporter proteins, nucleic acid molecules encoding human, transporter proteins, and uses thereof |
| 05/26/2005 | US20050112675 Polypeptides gene expressed in fat tissue ; measurement concentration; using antibodies |
| 05/26/2005 | US20050112669 Glutamate receptor transport protein peptide for use in treatment and prevention of nervous system and cell proliferative disorders |
| 05/26/2005 | US20050112666 Tumor necrosis factor related ligand |
| 05/26/2005 | US20050112665 Novel VEGF-like factor |
| 05/26/2005 | US20050112664 Nucleotide sequences coding for the citA gene |
| 05/26/2005 | US20050112663 Nucleic acids encodin gpolypeptide; therapy for genetic disorders, antiepileptic agents, hypotensive agents, cystic fibrosis, muscular disorders |
| 05/26/2005 | US20050112662 Human potassium channel genes |
| 05/26/2005 | US20050112660 Nucleotide sequence coding membrane protein; diagnosis, therapy of nervous system, psychological, brain disorders |
| 05/26/2005 | US20050112659 Human receptor proteins; related reagents and methods |